SEC Comment Letter 0000000000-23-001569 to Starpax Biopharma Inc. (CIK 0001960682)
Starpax Biopharma Inc. (CIK 0001960682)
Date: Feb. 15, 2023 · CIK: 0001960682 · Accession: 0000000000-23-001569
AI Filing Summary & Sentiment
File numbers found in text: 024-12149
Letter
United States securities and exchange commission logo February 15, 2023 Jean-François Pruneau Chief Operating Officer Starpax Biopharma Inc. 2500-1000 boul. Rene-Levesque West Montreal, Quebec. Canada H3B 5C9 Re:Starpax Biopharma Inc. Offering Statement on Form 1-A Filed February 9, 2023 File No. 024-12149 Dear Jean-François Pruneau: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nick Antaki
Show Raw Text
United States securities and exchange commission logo
February 15, 2023
Jean-François Pruneau
Chief Operating Officer
Starpax Biopharma Inc.
2500-1000 boul. Rene-Levesque West
Montreal, Quebec. Canada H3B 5C9
Re:Starpax Biopharma Inc.
Offering Statement on Form 1-A
Filed February 9, 2023
File No. 024-12149
Dear Jean-François Pruneau:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257
of Regulation A requires you to file periodic and current reports, including a Form 1-K which
will be due within 120 calendar days after the end of the fiscal year covered by the report.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Nick Antaki